RNA

Avidity Biosciences, Inc.distress 1/10 · well-funded / low risk

$11.98-2%today-28% from 52w high

atriumtherapeutics.comFounded 2025San Diego, CABiotechnology

Lead: Facioscapulohumeral

Revenue

$20M

Liquidity

$268M

Runway

2.1 yrs

Shares 1y

—

Price & events

-18.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.6%

-1.5%

-6.5%

-13.5%

—

-18.8%

All

Overview

Market Cap: $204.93M
Volume: 14.45K
52 Week Range: $11.55 – $16.54
Total Shares: 17.11M
Float Shares: 15.72M
% Held by Insiders: 4.27%
% Held by Institutions: 88.08%
RVOL: 0.07x

Pipeline stages · 3 programs

Del-desiran (AOC 1001)

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-08

AOC 1020

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-04-30

STP705

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-07-25

Pipeline · 7 trials · 7 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-08 Estimated 50% readout ~2026-10-15	Phase 3	AOC 1001 (del-desiran)	DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy	—	active not recruiting
2027-04-30 Estimated 50% readout ~2027-06-14	Phase 2	AOC 1044	DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44	—	active not recruiting
2027-07-25 Estimated 50% readout ~2027-09-08	Phase 2	STP705	Submental Fullness	—	not yet recruiting
2028-05 Estimated 50% readout ~2028-07-15	Phase 3	AOC-1020	Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome	—	recruiting
2029-05 Estimated 50% readout ~2029-07-15	Phase 3	AOC 1044	Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease, Musculoskeletal Diseases, Neuromuscular Diseases (NMD), Nervous System Diseases, Genetic Diseases, X-Linked, Hereditary, Neonatal Disease, Duchene Muscular Dystrophy, Congenital, DMD	—	not yet recruiting

Show all 7 trials · 2 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2030-04 Estimated 50% readout ~2030-05-16	Phase 2	AOC 1020	FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH	—	active not recruiting
2030-08 Estimated 50% readout ~2030-10-15	Phase 3	Del-desiran (AOC 1001)	Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease	—	enrolling by invitation